Avalo Therapeutics (Avalo Therapeutics) Momentum Rank : 2 (As of May. 17, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Momentum Rank?

Avalo Therapeutics has the Momentum Rank of 2.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Avalo Therapeutics's Momentum Rank

For the Biotechnology subindustry, Avalo Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Momentum Rank falls into.

Avalo Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalo Therapeutics (Avalo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

C6K0:Germany C6K0:Germany

Address

540 Gaither Road, Suite 400, Rockville, MD, USA, 20850

Website

https://www.avalotx.com

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Executives

Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd.	10 percent owner	PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan	officer: Interim CFO	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil	officer: Chief Medical Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski	officer: Chief Commercial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson	director	400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller	director	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Schond L. Greenway	officer: CFO & Treasurer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins	officer: Chief Medical Officer	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr	officer: Chief Commercial Officer	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022